Terms: = Germ cell tumor AND FUBP1, FBP, 8880, ENSG00000162613, FUBP AND Treatment
17 results:
1. Genomic alterations of oligodendrogliomas at distant recurrence.
Liu G; Bu C; Guo G; Zhang Z; Sheng Z; Deng K; Wu S; Xu S; Bu Y; Gao Y; Wang M; Liu G; Kong L; Li T; Li M; Bu X
Cancer Med; 2023 Aug; 12(16):17171-17183. PubMed ID: 37533228
[TBL] [Abstract] [Full Text] [Related]
2. circMMD reduction following tumor treating fields inhibits glioblastoma progression through fubp1/FIR/DVL1 and miR-15b-5p/FZD6 signaling.
Xu S; Luo C; Chen D; Tang L; Cheng Q; Chen L; Liu Z
J Exp Clin Cancer Res; 2023 Mar; 42(1):64. PubMed ID: 36932454
[TBL] [Abstract] [Full Text] [Related]
3. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract] [Full Text] [Related]
4. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
[TBL] [Abstract] [Full Text] [Related]
5. fubp1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract] [Full Text] [Related]
6. EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Zhang L; Liu Y; Wang M; Wu Z; Li N; Zhang J; Yang C
J Mol Cell Biol; 2017 Dec; 9(6):477-488. PubMed ID: 29272522
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
[TBL] [Abstract] [Full Text] [Related]
8. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.
Tanboon J; Williams EA; Louis DN
J Neuropathol Exp Neurol; 2016 Jan; 75(1):4-18. PubMed ID: 26671986
[TBL] [Abstract] [Full Text] [Related]
9. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and fubp1.
Cahill DP; Louis DN; Cairncross JG
CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
[TBL] [Abstract] [Full Text] [Related]
10. TCF12 is mutated in anaplastic oligodendroglioma.
Labreche K; Simeonova I; Kamoun A; Gleize V; Chubb D; Letouzé E; Riazalhosseini Y; Dobbins SE; Elarouci N; Ducray F; de Reyniès A; Zelenika D; Wardell CP; Frampton M; Saulnier O; Pastinen T; Hallout S; Figarella-Branger D; Dehais C; Idbaih A; Mokhtari K; Delattre JY; Huillard E; Mark Lathrop G; Sanson M; Houlston RS;
Nat Commun; 2015 Jun; 6():7207. PubMed ID: 26068201
[TBL] [Abstract] [Full Text] [Related]
11. tumor-specific mutations in low-frequency genes affect their functional properties.
Erdem-Eraslan L; Heijsman D; de Wit M; Kremer A; Sacchetti A; van der Spek PJ; Sillevis Smitt PA; French PJ
J Neurooncol; 2015 May; 122(3):461-70. PubMed ID: 25694352
[TBL] [Abstract] [Full Text] [Related]
12. Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management.
Sahebjam S; McNamara MG; Mason WP
CNS Oncol; 2013 Jul; 2(4):351-8. PubMed ID: 25054579
[TBL] [Abstract] [Full Text] [Related]
13. Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.
Eisenreich S; Abou-El-Ardat K; Szafranski K; Campos Valenzuela JA; Rump A; Nigro JM; Bjerkvig R; Gerlach EM; Hackmann K; Schröck E; Krex D; Kaderali L; Schackert G; Platzer M; Klink B
PLoS One; 2013; 8(9):e76623. PubMed ID: 24086756
[TBL] [Abstract] [Full Text] [Related]
14. Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th annual Frye-Halloran Brain tumor Symposium.
Jones PS; Dunn GP; Barker FG; Curry WT; Hochberg FH; Cahill DP
Neurosurg Focus; 2013 Feb; 34(2):E9. PubMed ID: 23373454
[TBL] [Abstract] [Full Text] [Related]
15. Frequent ATRX, CIC, fubp1 and IDH1 mutations refine the classification of malignant gliomas.
Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H
Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205
[TBL] [Abstract] [Full Text] [Related]
16. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity.
Pan X; Lee RJ
Int J Pharm; 2007 May; 336(2):276-83. PubMed ID: 17212981
[TBL] [Abstract] [Full Text] [Related]
17. Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens.
Smans KA; Ingvarsson MB; Lindgren P; Canevari S; Walt H; Stigbrand T; Bäckström T; Millán JL
Int J Cancer; 1999 Oct; 83(2):270-7. PubMed ID: 10471538
[TBL] [Abstract] [Full Text] [Related]
